Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gaucher disease

E Beutler1

  • 1Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, CA 92037, USA.

Current Opinion in Hematology
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Gaucher disease, a genetic disorder, progresses slowly. Enzyme replacement therapy is effective, but high doses are unnecessary for treating skeletal issues or other manifestations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

1342C mutation in Gaucher's disease.

Lancet (London, England)·1995
Same author

Triosephosphate isomerase deficiency: repetitive occurrence of point mutation in amino acid 104 in multiple apparently unrelated families.

American journal of hematology·1995
Same author

Gaucher disease.

Medicine·1995
Same author

Treatment regimens in Gaucher's disease.

Lancet (London, England)·1995
Same author

Molecular study of pyruvate kinase deficient patients with hereditary nonspherocytic hemolytic anemia.

The Journal of clinical investigation·1995
Same author

Erythrocyte fragility and chronic intermittent pigmenturia in a dog.

Journal of the American Veterinary Medical Association·1995
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Area of Science:

  • Genetics
  • Biochemistry
  • Medical Science

Background:

  • Gaucher disease is a genetic disorder caused by mutations in the glucocerebrosidase gene.
  • The disease involves glycolipid storage and typically has a slow progression.
  • Pulmonary involvement, once considered rare, is now recognized more frequently.

Purpose of the Study:

  • To review the natural history and clinical manifestations of Gaucher disease.
  • To evaluate the efficacy and optimal dosing of enzyme replacement therapy.
  • To discuss emerging therapeutic strategies, including gene therapy.

Main Methods:

  • Review of published literature on Gaucher disease.
  • Analysis of clinical data regarding disease progression and treatment response.

Related Experiment Videos

  • Assessment of current and future therapeutic approaches.

    • Main Results:

    • Enzyme replacement therapy with alglucerase or imiglucerase is effective for Gaucher disease.
    • Treatment response is independent of medication dosage for both general and skeletal manifestations.
    • Pulmonary involvement is more common than previously thought.

    Conclusions:

    • High doses of enzyme replacement therapy are not justified due to lack of dose-dependent efficacy.
    • Standard enzyme replacement is effective, but gene therapy faces significant challenges.
    • Further research is needed to overcome obstacles in developing gene therapy for Gaucher disease.